KQ-2206

N/A

Report date: 2024/04/15 14:25:29

Base Information

Drug NameKQ-2206
Drug Alias NameKQ-2206
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-CD70
TargetsCD70 antigen
Therapy Area/IndicationsCarcinoma, Renal Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesNovatim Immune Therapeutics (Zhejiang) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNovatim Immune Therapeutics (Zhejiang) Co Ltd
Inactive CompaniesN/A
Active IndicationsCarcinoma, Renal Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A